The Norwegian group was limited to women diagnosed while under surveillance for breast cancer because of BRCA2 mutations (prospective cases), which might explain why the Norwegian patients were, for the most part, diagnosed with early-stage cancers. This evidence concerns the gene BRCA2 and cancer.